• Binx Health

  Participated · Series D · Jan 2017

  Binx Health is a medical technology and diagnostic services provider. The company supplies testing, diagnostic and treatment services to clinics using its binx io testing instrument and a cartridge-based system. The binx io instrument and its cartridge are presented as the company’s core diagnostic products. According to the article, Binx Health recently completed a $65 million Series F financing. The reported financing round involved outside investors led by Hildred Capital with participation from EQT Life Sciences. binx health develops the binx io rapid molecular point-of-care testing platform, a CLIA‑waived solution that enables testing, diagnosis and treatment for chlamydia and gonorrhea during the same visit. The company supplies in‑clinic and at‑retail locations with its testing instrument and single‑use cartridges and is led by CEO Jeff Luber. It is expanding the platform into COVID‑19 testing by combining proprietary electrochemical detection with CRISPR methods. binx health plans to use recent funding to ramp manufacturing, scale its instrument and cartridges, expand sales in the U.S. and abroad, and further build out its proprietary software platform and data infrastructure. The company describes itself as a healthcare technology and diagnostics firm focused on rapid molecular point‑of‑care testing. Atlas Genetics is a Bath, England–based company that develops ultra-rapid point-of-care (POC) molecular diagnostic tests for infectious diseases. Its io® system is a molecular diagnostic platform built on a patent-protected electrochemical sensor technology. The system uses an integrated cartridge containing all reagents designed to accept an unprocessed clinical specimen; each cartridge can detect up to 24 different genetic targets. The company plans to use recent financing to support clinical trials and the commercial launch of a second test for detection of both Chlamydia and Gonorrhoea, targeting US regulatory approvals around the end of 2017. Atlas also intends to further develop its diagnostics menu and expand cartridge manufacturing capacity at Bespak. The company maintains a commercial office in Boston and is led by CEO Dr. John Clarkson. The firm reported closing a $35m Series D to fund these activities. Atlas Genetics develops the io(R) system, a novel point-of-care molecular diagnostic platform based on a patent‑protected electrochemical sensor technology that combines speed, accuracy and low manufacturing costs. The fully integrated cartridge contains all reagents, accepts an unprocessed clinical specimen and completes sample preparation, DNA amplification and electrochemical detection. Each cartridge can run up to 24 different tests from a single patient sample. The system is at an advanced stage of development and is expected to launch in Europe with a Chlamydia test later this year. The company plans to use the new funding to launch the io(R) system, initiate U.S. clinical trials and expand its test menu in STI and HAI markets. Atlas is led by CEO Dr John Clarkson. Atlas Genetics develops rapid decentralized and point-of-care (POC) molecular diagnostic tests for a range of infectious diseases, including sexually transmitted and hospital-acquired infections. Its Atlas io™ system is a patented electrochemical sensor–based molecular diagnostic platform that combines speed and accuracy while removing the need for costly optical components. The company is led by CEO Dr John Clarkson. Atlas intends to use the new funding to complete the transfer to manufacture of the Atlas io™ system and to file for European approval of its first Chlamydia test. The article reports a Series B financing, reflecting an active fundraising stage to support product commercialization and regulatory approval.

• Abyrx

  Participated · Equity · Dec 2016

  Abyrx develops, manufactures and provides specialty biosurgical products, with a core focus on bone putty used in surgical procedures. The company says it will use new capital to manage demand for its bone putty products and to accelerate pipeline development activities. Abyrx expanded its exclusive worldwide license with Bezwada Biomedical to include development, manufacture and commercialization of Bezwada’s proprietary adhesive technology for soft tissue applications. That expanded agreement gives Abyrx exclusive access to proprietary materials and manufacturing it will use to develop products for surgical site hemostasis, sealing and fixation. The company was founded in 2013 and is led by President and CEO John J. Pacifico. Abyrx is based in Irvington, N.Y.

• Aleva Neurotherapeutics

  Participated · Series C · May 2016

  Aleva Neurotherapeutics' flagship product is the directSTIM deep brain stimulation (DBS) system, which incorporates first-in-class directional electrode technology designed to provide more precise, optimized stimulation and potentially reduce side effects. The company was awarded the CE Mark for directSTIM and will begin direct sales through a post-market clinical follow-up study in select European neurological clinics. Aleva says it is the only emerging technology company awarded a CE Mark for DBS and has published pilot results supporting the potential of directional stimulation to improve surgical outcomes. The company has also formed a joint venture, Adept Neuro SA with Dixi Medical SAS, targeting regulatory approval for its core technology in epilepsy surgery. With European market entry secured, Aleva plans to drive efforts toward US market entry and the US FDA regulatory process. Financially, Aleva announced an $8 million first closing of a Series E financing and has previously raised over $50 million from institutional and private investors. Aleva Neurotherapeutics is an EPFL spinoff developing implants for directional deep brain stimulation (DBS) targeting Parkinson’s disease and Essential Tremor. Its core products are directSTIM, a complete directional DBS system for long-term therapy, and spiderSTIM, a solution for intra-surgical placement of DBS electrodes. The company says its devices aim to improve precision and efficiency while reducing side effects compared with current DBS approaches. Aleva reported successful results from its directSTN pilot study published in Brain, supporting the potential benefit of directional stimulation. Proceeds from the recent financing will be used to complete acquisition of a CE Mark for directSTIM and the company has completed a first closing while still accepting qualified investors for a limited time. Aleva also maintains a development agreement with Nuvectra to combine its directional lead technology with Nuvectra’s neurostimulation platform and a supply and manufacturing agreement with Integer. To date the company has raised USD 46 million from institutional and private investors. Aleva Neurotherapeutics develops next-generation neurostimulation technologies and devices for Deep Brain Stimulation (DBS) based on its proprietary microDBS™ technology. The company has developed two products: directSTIM™, a directional DBS system for long-term therapy in Parkinson’s Disease and Essential Tremor, and spiderSTIM™, a solution for intra-surgical placement of DBS electrodes. Aleva intends to use the new funding to obtain the CE mark for directSTIM™ in 2017. The company has raised $42M to date. Leadership includes founder and CTO André Mercanzini, PhD, and Executive Chairman Oern Stuge, MD. Aleva is a spin-off from the EPFL Microsystems Laboratory in Lausanne. Aleva Neurotherapeutics is an EPFL spin-off developing next-generation neurostimulation technologies for Deep Brain Stimulation (DBS) in major neurological indications such as Parkinson’s disease and essential tremor. The company’s products are based on its proprietary microDBS technology and are designed to be more precise and efficient than current DBS approaches while causing fewer side effects. Aleva has developed two products: directSTIM, a complete directional DBS system for long-term therapy, and spiderSTIM, a solution for intra-surgical placement of DBS electrodes. The company reports it has raised EUR 14.5 million from private and institutional investors to advance its programs. Aleva says it has reached major milestones and is entering a crucial phase to advance and commercialize its directional DBS lead. The recent appointment of Philippe Dro to the Board is intended to accelerate Aleva’s commercial and business development activities so its products can reach the market for patients. Aleva Neurotherapeutics develops next-generation neurostimulation products based on its proprietary microDBS™ technology for target-specific deep brain stimulation. Its pipeline includes directSTIM™, an electrode compatible with existing DBS systems; spiderSTIM™, a full intra-surgical and long-term solution; and cortiSTIM™ for cortical stimulation. All products are designed to be compatible with existing DBS technologies and aim to reduce side effects, complications and costs associated with DBS therapy. The company says proceeds will advance its products through clinical development up to CE marking and accelerate pipeline development and partner discussions. Aleva is a spin-off from the EPFL Microsystems Laboratory of Prof. Philippe Renaud and was founded in 2010. Prior to this round the company had raised EUR 12.8 million from private and institutional investors.

• AM Pharma

  Participated · Equity · Sep 2014

  AM-Pharma B.V. is a clinical-stage biopharmaceutical company developing recAP, a recombinant human alkaline phosphatase therapeutic for acute kidney injury (AKI), particularly sepsis-associated AKI (SA-AKI). recAP has Fast Track designation from the U.S. FDA (awarded in 2016) and the company completed a 301-patient Phase II trial. The planned multinational pivotal Phase III trial aims to enroll up to 1,400 SA-AKI patients at sites in approximately 12 countries. Recent financing is intended to support that Phase III trial and to fund Marketing Authorization Application readiness activities, including CMC validation and commercial manufacture. AM-Pharma has raised additional capital bringing recent fundraising to a total of €163m, enabling the company to advance recAP toward registration and commercialization. The company's investor syndicate includes Cowen Healthcare Investments, the European Investment Bank and earlier backers such as LSP, Andera Partners, Forbion, Ysios Capital, Kurma Partners, ID Invest Partners, BB Pureos Bioventures and Gilde Healthcare. AM-Pharma is a clinical-stage biopharmaceutical company focused on recAP, a recombinant human alkaline phosphatase therapeutic for acute kidney injury (AKI). recAP is a proprietary recombinant human AP constructed from two human isoforms with a dual mechanism of action: dephosphorylation of lipopolysaccharides (LPS) and extracellular ATP to reduce inflammation and protect the kidney. The candidate reported promising Phase II STOP-AKI results in 301 sepsis patients, including a relative reduction in mortality of more than 40% and significant long-term kidney-function improvements; results were published in JAMA. The programme holds FDA Fast Track designation (2016) and the company is preparing a pivotal Phase III study in sepsis-associated AKI to enroll about 1,400 patients across approximately 12 countries. AM-Pharma plans to submit market-authorization applications in the US and Europe following successful completion of the single pivotal Phase III trial. The company is also exploring recAP in other indications including ulcerative colitis, necrotizing enterocolitis and hypophosphatasia. Financially, AM-Pharma has raised over €195m in equity and debt to date and recently secured €116m to support its Phase III programme. AM-Pharma, based in Bunnik, the Netherlands, focuses on the preclinical and clinical development of recombinant human Alkaline Phosphatase (recAP) as a treatment for inflammatory diseases. Its lead program is recAP for acute kidney injury (AKI) related to sepsis; the company also intends development for ulcerative colitis and hypophosphatasia and may pursue an oral formulation for UC. recAP is produced by cGMP manufacture for clinical trials and potential commercialization. Results from the current Phase II trial in AKI were expected in the second half of 2016. AM-Pharma built on positive Phase II data with bovine AP to develop the recombinant human form for future trials and commercialization. Since inception the company has raised €67 million from a syndicate of international investors and completed a €12.2 million financing in September 2014 to support the Phase II study and oral formulation work. AM-Pharma develops recAP, a proprietary recombinant human Alkaline Phosphatase optimized as an injectable for Acute Kidney Injury (AKI) and an oral formulation for Ulcerative Colitis (UC). The company plans to complete a 290‑patient, four‑arm, Phase II dose‑finding, placebo‑controlled, Phase III‑enabling study in AKI and to start Phase II development in UC. Proceeds from the recent financing will also support continued development of an oral recAP formulation. AM-Pharma bases its development on prior positive Phase II results with bovine Alkaline Phosphatase and manufactures recAP to cGMP standards for clinical supply. The company is headquartered in Bunnik, The Netherlands. Financially, AM-Pharma has previously raised €29.2M in Q4 2011 and has now closed an additional €12.2M financing to advance its clinical programs. AM-Pharma focuses on preclinical and clinical development of a human recombinant Alkaline Phosphatase (AP) as a protective treatment for severe inflammatory diseases. The company aims to replace bovine AP with its proprietary recombinant human AP for future trials and commercialization. Clinical proof-of-concept with bovine AP showed positive Phase II results in AKI and a Phase II trial in severe Ulcerative Colitis, supporting the development path. The current plan is to finalize GMP production of the recombinant AP and advance it through the end of Phase II. Management highlights the high unmet medical need in AKI, a market the article values at roughly USD 2 billion with over 700,000 annual deaths. AM-Pharma is based in Bunnik, The Netherlands.

• Atlas

  Participated · Series B · Apr 2014

  Atlas develops ultra-rapid decentralized and point-of-care (POC) diagnostic tests for a range of infectious diseases built around its Atlas io system. The io system uses a patent-protected electrochemical sensor technology that removes the need for costly optical components and supports multiplex detection. The platform consists of an inexpensive Reader and a disposable cartridge and is designed to deliver accurate results within 30 minutes. Atlas completed the final tranche of a £16.9m Series B and the funds will be used to complete transfer to manufacture and to file for European approval of its first Chlamydia test. Clinical trials were scheduled for 2014 with a planned rollout in Europe and the United States pending regulatory approvals. The company, established in 2005, has head office and laboratory facilities near Bath and is targeting initial launches for Chlamydia and Gonorrhoea, conditions for which over 50 million tests are carried out annually in Europe and the US; the worldwide infectious-disease IVD market is cited at around US$9 billion.

No current team members are available.